文献速递前列腺癌

美洲原住民前列腺癌特征与癌症特异性死亡率研究

Prostate cancer characteristics and cancer-specific mortality of Native American patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-11-06

基于SEER数据库2004-2016年357,289例前列腺癌患者,比较美洲原住民与白种人的癌症特异性死亡率。美洲原住民就诊时分期分级更差,但经倾向评分匹配调整后,10年癌症特异性死亡率无显著差异,种族非独立预测因子。

要点

  • 美洲原住民前列腺癌患者就诊时PSA更高、高危比例更高、晚期比例更高。
  • 匹配调整后,美洲原住民与白种人的10年癌症特异性死亡率无显著差异。
  • 应努力让美洲原住民像白种人一样在更早更有利的阶段诊断前列腺癌。

核心结论

  • 美洲原住民前列腺癌患者就诊时分期和分级更差,但调整这些特征后癌症特异性死亡率不高于白种人。
  • 前列腺癌预后在美洲原住民与白种人之间无差异。

研究设计与样本

  • 使用SEER数据库2004-2016年数据,纳入357,289例白种人和美洲原住民前列腺癌患者。
  • 进行1:4倾向评分匹配(匹配分期、分级和其他患者特征),采用累积发生率图和竞争风险回归模型分析。

主要发现

  • 美洲原住民患者占研究队列的1804例(0.5%)。
  • 美洲原住民患者PSA更高(8 ng/ml vs 6.3 ng/ml),D'Amico高危前列腺癌比例更高(30.8% vs 24.8%),T3/T4期比例更高(5.5% vs 3.7%),N1期比例更高(4.5% vs 2.8%),M1期比例更高(7.5% vs 3.9%),所有p < 0.001。
  • 倾向评分匹配后,TanyN0M0患者中美洲原住民与白种人的10年癌症特异性死亡率为5.7% vs 6.2%。
  • TanyN1和/或M1患者中,10年癌症特异性死亡率为64.3% vs 63.3%(两者p = 0.8)。
  • 竞争风险回归中,美洲原住民种族不是癌症特异性死亡率的独立预测因子。

临床怎么用

  • 临床应关注美洲原住民前列腺癌患者就诊时更晚期的特征,努力实现早期诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historical epidemiological data indicate that Native American patients may have worse prostate cancer (PCa) characteristics than Caucasian patients (CAP). To test for cancer-specific mortality (CSM) differences among Native American vs. CAP, the most contemporary version of the SEER database (Surveillance, Epidemiology, and End Results database [2004-2016]) was used. METHODS: Descriptives and time trend analyses focused on a combined cohort of 357,289 Caucasian and Native American PCa patients of all stages. After 1:4 propensity-score (PS) matching for stage, grade, and other patient characteristics, cumulative incidence plots, and competing-risks-regression-models (CRR) were used, with further stratification according to non-metastatic (TanyN0M0) vs. metastatic (TanyN1 and/or M1) stages. RESULTS: Native American patients accounted for 1804 (0.5%) of the study cohort. Native American patients had higher PSA (8 ng/ml vs. 6.3 ng/ml), higher rate of D'Amico high-risk PCa (30.8 vs. 24.8%), higher rate of T3/T4-PCa (5.5 vs. 3.7%), higher rate of N1 stage (4.5 vs. 2.8%), and higher rate of M1 stage (7.5 vs. 3.9%, all p < 0.001) than CAP. In TanyN0M0 patients after PS-matching, 10-year CSM was 5.7 vs. 6.2% in Native American vs. CAP. In TanyN1 and/or M1 patients, 10-year CSM was 64.3 vs. 63.3% in Native American vs. CAP, (both p = 0.8). In CRR, Native American race did not represent an independent predictor of CSM. CONCLUSIONS: Native American patients have more unfavorable stage and grade at presentation. However, after adjustment for these characteristics, CSM in Native American patients is not higher than in CAP. In consequence, PCa prognosis does not differ between Native American and Caucasian race. Therefore, efforts should be made to diagnose PCa in Native Americans at an earlier and more favorable stage like in CAP.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Deuker M, Knipper S, Pecoraro A, et al. Prostate cancer characteristics and cancer-specific mortality of Native American patients. Prostate Cancer Prostatic Dis. 2019. PMID: 31695139. doi:10.1038/s41391-019-0184-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。